Catalyst Pharmaceuticals jumps on report of potential acquisition interest

Catalyst Pharmaceuticals (CPRX) is up 8.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears primarily tied to takeover speculation after a report said Italian drugmaker Angelini Pharma is exploring a potential acquisition of Catalyst. The rally may also be amplified by existing bullish positioning given Catalyst’s recent momentum and a near-term earnings catalyst.

Details:

A report described Angelini Pharma as working with advisers to study a possible purchase of Catalyst, with discussions said to be at a preliminary stage.

CPRX has been trading near recent highs in late April, which can make M&A headlines more impactful as they reset investor expectations for an acquisition premium.

Catalyst’s most recently discussed fundamentals have centered on continued commercial execution across its rare-disease portfolio, which can make it a plausible target for a buyer seeking durable cash flows.

The company is scheduled to report its next quarterly results on May 6, 2026, which can raise event-driven interest and options activity around the name.

Sources:

Investing.com, MarketScreener, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CPRX Insider Trading Activity

$CPRX insiders have traded $CPRX stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $CPRX stock by insiders over the last 6 months:

BRIAN ELSBERND (Chief Compliance/Legal Officer) sold 40,000 shares for an estimated $908,000
MOLLY HARPER has made 0 purchases and 3 sales selling 26,746 shares for an estimated $621,920.
CARMEN JEFFREY DEL (Chief Commercial Officer) sold 10,983 shares for an estimated $256,244

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive CPRX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CPRX Hedge Fund Activity

We have seen 180 institutional investors add shares of $CPRX stock to their portfolio, and 179 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 1,147,565 shares (+200.6%) to their portfolio in Q4 2025, for an estimated $26,784,167
MORGAN STANLEY added 1,089,775 shares (+59.1%) to their portfolio in Q4 2025, for an estimated $25,435,348
RENAISSANCE TECHNOLOGIES LLC removed 894,753 shares (-25.2%) from their portfolio in Q4 2025, for an estimated $20,883,535
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 829,923 shares (-74.8%) from their portfolio in Q4 2025, for an estimated $19,370,402
MACQUARIE GROUP LTD removed 761,740 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,779,011
PACER ADVISORS, INC. removed 620,801 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $14,489,495
DIMENSIONAL FUND ADVISORS LP added 538,128 shares (+21.9%) to their portfolio in Q4 2025, for an estimated $12,559,907

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$CPRX Analyst Ratings

Wall Street analysts have issued reports on $CPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Buy" rating on 11/07/2025

To track analyst ratings and price targets for $CPRX, check out Quiver Quantitative's $CPRX forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.